NL-OMON54726
Recruiting
Not Applicable
Identification of paediatric Hodgkin lymphoma biomarkers and novel therapeutic targets. - Hodgkin-biomarkers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hodgkin disease
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 230
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in the Hodgkin lymphoma group, a subject
- •must meet all of the following criteria:
- •Diagnosis of classical Hodgkin Lymphoma confirmed by reference pathology
- •Patient aged below 18 at time of diagnosis
- •· Treatment according the European Network of Paediatric Hodgkin\`s Lymphoma
- •Second International Inter\-Group Study for Classical Hodgkin\*s Lymphoma in
- •Children and Adolescents (EuroNet\-PHL\-C2\) protocol or treatment for relapsed or
- •refractory patients or according to the Open\-label, Uncontrolled, Multicenter
- •Phase II Trial of MK\-3475 (Pembrolizumab) in Children and Young Adults with
- •Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early)
Exclusion Criteria
- •\- HIV positivity
- •\- Other underlying immunologic disorders causing an inadequate or overactive
- •immune response, with the exception of Epstein Barr Virus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Hodgkin-biomarkersPediatric Hodgkin lymphomaNL-OMON28180Erasmus MC - Sophia320
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin?s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin?s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1EUCTR2007-004092-19-NLMartin Luther University of Halle/Wittenberg
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin?s Lymphoma Group First international Inter-Group Study for classical Hodgkin?s Lymphoma in Children and Adolescents - EuroNet-PHL-C11st and 2nd line therapy for childhood Hodgkin?s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.MedDRA version: 8.1 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's diseaseEUCTR2006-000995-33-NLMartin-Luther-University Halle-Wittenberg1,200
Active, not recruiting
Phase 1
EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Studyfor nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents - EuroNet-PHL-LP1The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.EUCTR2007-004092-19-CZMartin Luther University of Halle/Wittenberg250
Active, not recruiting
Phase 1
Evaluation of the therapy of Hodgkin’s Lymphoma in Children and AdolescentsEUCTR2007-004092-19-DEMartin Luther University of Halle/Wittenberg200